Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Edwards Lifesciences

Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Investors Business Daily

Is Edwards Lifesciences Stock Underperforming the S&P 500?

Edwards Lifesciences has recently underperformed the broader S&P 500, yet analysts remain moderately optimistic about the stock's potential.

Barchart

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 17 analysts.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Edwards Skids On Weak Expectations For Its Bread-And-Butter Moneymaker

Edwards Lifesciences stock fell Friday after the company said its TAVR segment will face numerous challenges in the fourth quarter.

Investors Business Daily

How Is Edwards Lifesciences' Stock Performance Compared to Other Medical Devices Stocks?

While Edwards Lifesciences has underperformed the broader medical devices industry recently, analysts are moderately bullish on the stock's prospects.

Barchart

Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?

Despite Edwards Lifesciences’ underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Edwards Crashes 31% After Slashing Guidance For Its Biggest Moneymaker

Edwards Lifesciences stock plummeted Thursday after the medtech cut its outlook for TAVR sales following a mixed second-quarter report.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

What You Need to Know Ahead of Edwards Lifesciences' Earnings Release

Edwards Lifesciences is expected to release its second-quarter earnings this month, and analysts expect a single-digit profit increase.

Barchart

Edwards Lifesciences Trying To Close In On Key Technical Measure

Edwards Lifesciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Edwards Lifesciences Stock: Is EW Underperforming the Healthcare Sector?

Edwards Lifesciences has recently underperformed the Healthcare sector, but Wall Street analysts anticipate a modest upside for the stock.

Barchart

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal

Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.

Investors Business Daily

This 'Critical' Business Helped Edwards Lifesciences Offset Its TAVR Miss

Edwards Lifesciences stock underperformed its peers on Friday, sliding on light sales of its transcatheter aortic heart-valve replacements.

Investors Business Daily

Medical device companies pay millions to NHS while pushing products, says study

Pharmaceutical equipment firms are funding NHS staff and training while promoting sales

The Guardian - UK

Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark

Edwards Lifesciences sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Edwards Lifesciences' Fortunes Are Reaccelerating, Analyst Says — But Its Stock Isn't

There are signs Edwards' heart valve replacement technology is reaccelerating, an analyst said Wednesday. But EW stock only inched ahead.

The Street

'5 ultracheap stocks with the best return on investment' — Morningstar

The stocks had to jump through four significant hoops to make it onto Morningstar's roster.

Investors Business Daily

Edwards Lifesciences Sinks Despite An Earnings Beat, Outlook Increase

Edwards Lifesciences stock fell late Wednesday after the medtech company reported Q2 earnings, narrowly topping profit and revenue expectations.

Investors Business Daily

Edwards Lifesciences Stock Shows Improved Relative Price Strength

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall: Market Rally Resilient After Fed Surprise; Tesla Ends Record Run

The market rally held up, for now, amid a Fed forecast of two more rate hikes. Tesla ended a big win streak. Medical product firms flashed buy signals.

Investors Business Daily

Edwards Lifesciences Surges As Signs Point To 'Green Shoots Around The Corner'

There are signs of green shoots around the corner for Edwards Lifesciences, an analyst said Wednesday as EW stock surged.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022

Upgrades

Investors Business Daily

Edwards Plummets After Slashing Profit Guidance As Challenges Mount In The U.S.

Edwards slashed its profit outlook, leading EW stock to plummet Friday amid continued hospital staffing and exchange-rate challenges.

Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Edwards Lifesciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on Edwards Lifesciences (NYSE:EW). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Analyzing Edwards Lifesciences's Short Interest

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 166.36% since its last report. The company recently reported that it has 5.87 million shares sold short, which is 2.85% of all regular shares that are available for trading.

1 2 3

People

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.